|
2020/12/22 |
2021/3/31 |
2021-04-20 (treatment for malignant pleural
effusion) |
2021/9/2 |
2021/12/15 |
2022/3/30 |
2022/5/2 |
2022/7/15 |
2023/3/15 |
2023/11/28 |
IL-6, pg/ml |
157.1 |
– |
– |
– |
– |
– |
– |
– |
– |
– |
SCC (Squamous cell carcinoma-associated antigen), ng/ml (0-1.5 pg/ml) |
2.1 |
0.6 |
1.2 |
1.2 |
4 |
1 |
1.3 |
0.8 |
1.3 |
1.6 |
ProGRP (Gastrin-releasing peptide precursor), pg/ml (25.3-77.8 pg/ml) |
43.94 |
26.43 |
28 |
37.1 |
48.34 |
36.8 |
42.69 |
31.8 |
32.00 |
34.05 |
NSE (Neuron-specific enolase), ng/ml (0-16.3 pg/ml) |
42.32 |
15.52 |
29.88 |
9.43 |
12.79 |
12.5 |
11.56 |
11.45 |
8.93 |
13.13 |
CYFRA211, ng/ml |
7.67 |
3.42 |
4.08 |
2.29 |
3.26 |
2.25 |
1.61 |
2.8 |
2.59 |
17.6 |
CA199, U/mL (0-25 U/mL) |
17.7 |
20.9 |
20.7 |
14.4 |
16.4 |
15.1 |
13 |
17.4 |
13.6 |
10.1 |
CEA (Carcinoembryonic antigen), ng/ml (0-5 ng/ml) |
13.43 |
43.08 |
33.68 |
9.3 |
6.85 |
14.31 |
12.83 |
7.97 |
10.82 |
3.82 |
AFP(Alpha-fetoprotein), ng/ml (0-9 ng/ml) |
1.96 |
6.25 |
11.4 |
3.06 |
3.89 |
3.32 |
3.04 |
3.2 |
3.05 |
3.02 |
CA153, U/mL (0-14 U/mL) |
– |
34.5 |
42.2 |
11.4 |
8.1 |
20.8 |
22.2 |
12.9 |
12.60 |
– |
CA125, U/mL (0-35 U/mL) |
– |
347.3 |
604.7 |
51.6 |
7.4 |
129.3 |
134.7 |
20.7 |
31.7 |
– |